Surfactant phospholipid DPPC downregulates monocyte respiratory burst via modulation of PKC
Pulmonary surfactant phospholipids have been shown previously to regulate inflammatory functions of human monocytes. This study was undertaken to delineate the mechanisms by which pulmonary surfactant modulates the respiratory burst in a human monocytic cell line, MonoMac-6 (MM6). Preincubation of MM6 cells with the surfactant preparations Survanta((R)), Curosurf((R)) or Exosurf Neonatal ((TM)) inhibited the oxidative response to either lipopolysaccharide (LPS) and zymosan or phorbol-12-myristate-13-acetate (PMA) by up to 50% (P<0.01). Preincubation of MM6 cells and human peripheral blood monocytes with dipalmitoyl phosphatidylcholine (DPPC), the major phospholipid component of surfactant, inhibited the oxidative response to zymosan. DPPC did not directly affect the activity of the NADPH oxidase in a MM6 reconstituted cell system, suggesting that DPPC does not affect the assembly of the individual components of this enzyme into a functional unit. The effects of DPPC were evaluated on both LPS/zymosan and PMA activation of Protein Kinase C (PKC), a ubiquitous intracellular kinase, in MM6 cells. We found that DPPC significantly inhibited the activity of PKC in stimulated cells by 70% (P<0.01). Western blotting experiments demonstrated that DPPC was able to attenuate the activation of the PKCdelta isoform but not PKCalpha. These results suggest that DPPC, the major component of pulmonary surfactant, plays a role in modulating leukocyte inflammatory responses in the lung via down regulation of PKC, a mechanism that may involve the PKCdeltaisoform.
|Authors:||Tonks A, Parton J, Tonks AJ, Morris RH, Finall A, Jones KP, Jackson SK|
|Journal:||Am J Physiol Lung Cell Mol Physiol., 288(6):L1070-1080|
|PubMed:||Find in PubMed|